171 results
Page 3 of 9
8-K
eks 70dzubyrfx
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.1
017rp3
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.1
x10wd8 nmxg7v
12 May 22
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
7:05am
8-K
lfibzc2st4
11 May 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
byerv
1 Apr 22
Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
7:05am
8-K
8pi984a
1 Apr 22
Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
7:05am
8-K
EX-99.1
lz9tp t0cgigqp2inc
31 Mar 22
Aravive Reports Fourth Quarter and Full Year 2021
4:05pm
8-K
EX-10.1
ix9nva1b q4k5
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
8-K
EX-99.1
kraz 71eauu3
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
8-K
EX-10.2
wcji6lgc2m
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
424B5
w5d l6q2ieh60q0
31 Mar 22
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
wcsgqtj55iv6endk1
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm
8-K
EX-99.1
cxuwoh8g38m4z
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
g2dv5x
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
nv16au5
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am
8-K
EX-99.1
h1zq cbdc0sno
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am